Immunosuppressive treatment of motor neuron syndromes. As effective, perhaps more so, than plasmapheresis. Products that contain IgA should not be given to patients with selective IgA deficiency. Treatment should be started as soon as possible. 15.2 22.6 Patients in this study with serologically proven Campylobacter infection did less well, as was also the case for patients with GM1 antibodies.
Adverse events are uncommon and usually managed by slowing the infusion rate.
A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. New Eng J Med. Intravenous immunoglobin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Plasmapheresis Effective treatment in both AIDP and CIDP but not available in many institutions and compares unfavorably with IVIG in regard to both technical difficulties and adverse events. If used, should be started as soon as possible.